Bolt Biotherapeutics, Inc.:PRA-216在哮喘、慢阻肺、特应性皮炎及嗜酸性食管炎领域的二期临床数据,预计将于2027年第二季度公布。
Bolt Biotherapeutics, Inc.:PRA-216在哮喘、慢阻肺、特应性皮炎及嗜酸性食管炎领域的二期临床数据,预计将于2027年第二季度公布。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.